Prioritization of Vaccines for Introduction in the National Immunization Program in the Republic of Korea
Won Suk Choi,
Yeonhee Sung,
Jimin Kim,
Hyeri Seok,
Young J. Choe,
Chelim Cheong,
Jahyun Cho,
Dong Woo Lee,
Jee Yeon Shin,
Su-Yeon Yu
Affiliations
Won Suk Choi
Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Republic of Korea
Yeonhee Sung
Research Support Team, Korea University Research & Business Foundation, Seoul 02841, Republic of Korea
Jimin Kim
Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul 04933, Republic of Korea
Hyeri Seok
Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Republic of Korea
Young J. Choe
Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul 02841, Republic of Korea
Chelim Cheong
Department of Pharmacy, College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea
Jahyun Cho
Graduate School of Public Health, Seoul National University, Seoul 08826, Republic of Korea
Dong Woo Lee
Division of Immunization, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Osong 28159, Republic of Korea
Jee Yeon Shin
Division of Immunization, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Osong 28159, Republic of Korea
Su-Yeon Yu
Department of Pharmacy, College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea
This study presents a framework for determining the prioritization of vaccine introduction in the National Immunization Program (NIP) of the Republic of Korea, with a focus on case examples assessed in 2021 and 2023. We describe the predefined criteria for evaluating the prioritization of vaccines in the NIP and the established process in the Republic of Korea. These criteria included disease characteristics, vaccine characteristics, rationality and efficiency of resource allocation, and the acceptance of immunization. The process of prioritizing NIP introduction involved several sequential steps: a demand survey, evidence collection, preliminary evaluation, priority evaluation, and decision making. In 2021 and 2023, 14 and 25 committee members participated in evaluating the prioritization of vaccines in the NIP, respectively. Overall, 13 and 19 NIP vaccine candidates were included in the 2021 and 2023 evaluations, respectively. Through the Delphi survey and consensus processes, the priority order was determined: vaccination against Rotavirus infection was the top priority in 2021, while Influenza 4v (for chronic disease patients) took precedence in 2023. This study demonstrates an evidence-based decision-making process within the healthcare field. The outlined approach may provide valuable guidance for policymakers in other countries seeking to prioritize the inclusion of new vaccines in their NIP.